Joe Schwartz's questions to WAVE Life Sciences Ltd (WVE) leadership • Q3 2024
Question
Jenny, on for Joe Schwartz of Leerink Partners, asked about the WVE-006 RNA editing program, seeking to confirm if the 60% M-AAT protein level suggests editing efficiency could still increase, if Wave is at the bottom of the dose curve, and how much higher the dosage could go.
Answer
CEO Paul Bolno confirmed that achieving 60% M-protein with the lowest single dose is a very encouraging surrogate for editing efficiency and that they are at the low end of the dose curve. He expects efficiency to increase with repeat dosing, based on preclinical data. He also stated they have ample room to increase the dose, are already dosing higher in healthy volunteers, can dose higher than inclisiran, and will also explore extending the dosing interval for less frequent administration.